“Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia” (2008) Swiss Medical Weekly, 138(2930), pp. 420–426. doi:10.4414/smw.2008.12120.